TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
The new program includes upstream and downstream process development and large-scale GMP production.
The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
Amarex Clinical Research guides its client to phase II of FDA trials
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
